The liver disease treatment market was valued at USD 22.23 Billion in 2025. The market is expected to grow at a CAGR of 10.40% during the forecast period of 2026-2035, with the values likely to reach USD 59.79 Billion by 2035. The market growth is fueled by the increasing adoption of antiviral therapies, immunosuppressants, and targeted treatments. Rising awareness of liver health and early diagnosis through advanced non-invasive imaging and biomarker testing is expected to enhance market value during the forecast period. Expansion of personalized therapies and growing patient access to treatment options are likely to drive growth.
Base Year
Historical Period
Forecast Period
Recent data reveals that over 100 million individuals in the United States are affected by liver or hepatic disease. This rising burden of liver disease is a major growth driver for effective treatments.
The surge in the approval of innovative drugs for the treatment of liver disease by the regulatory bodies is a significant market trend.
The market value is impacted by the rising preference for combination therapies and the advancements in diagnostic technologies.
Compound Annual Growth Rate
10.4%
Value in USD Billion
2026-2035
*this image is indicative*
A liver disease directly affects the liver and progresses slowly unlike acute liver failure. Untreated liver disease can result in liver cancer or liver failure. Treatments for liver disease can include antiviral drugs to treat hepatitis, steroids for managing liver inflammation, and others. The increasing cases of liver disease due to factors such as obesity, viral infections, and alcohol consumption is a major growth driver of the market. Further, the rising development of novel therapeutics such as immune modulators and gene therapies that offer better clinical benefits are expected to augment the market demand. Moreover, improvements in diagnostic tools including imaging techniques and biomarker tests for diagnosing and monitoring liver diseases is also contributing to the market growth.
Rising Prevalence of Liver Diseases to Drive Market Growth
Recent data reveals that over 100 million individuals in the United States are affected by liver or hepatic disease. It is reported that 4.5 million adults have been diagnosed with liver disease. However, around 80 to 100 million U.S. adults are estimated to have undiagnosed fatty liver disease in varying stages. The increasing prevalence of liver diseases is expected to drive the demand for effective treatment. Additionally, the growing geriatric population, which is more prone to liver diseases, is poised to contribute to the market demand.
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
The Expert Market Research report titled “Liver Disease Treatment Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Breakup by Disease Type
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy, among others. The antiviral drugs segment covers a significant market share due to the high prevalence of viral hepatitis such as hepatitis B and C. The development of new antiviral agents with higher efficacy and better safety profiles further boosts the market share. Moreover, the chronic nature of hepatitis B and C, if not treated effectively, necessitates long-term antiviral therapy, which is likely to augment the market demand in the forecast period.
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share due to the considerable burden of liver diseases, the presence of advanced healthcare infrastructure, and a strong focus on research and development activities in the region. The high healthcare expenditure allows access to innovative therapies and also supports the development of new treatments in the region. Moreover, the presence of key players in the United States that are engaged in developing antiviral and targeted therapies for liver diseases is expected to bolster the market growth.
The key features of the market report comprise the patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
American multinational medical devices and health care company Abbott Laboratories is a prominent player in the market. Its drug SILLIVER® (Silymarin) is indicated for the treatment of liver diseases such as liver cirrhosis, acute hepatitis, and toxic metabolic liver damage. Silymarin is also known to protect against liver damage by general anesthesia.
Headquartered in Princeton, New Jersey, Bristol-Myers Squibb is widely recognized for its innovative treatments including therapies for liver diseases. One of its key medications is the FDA-approved Daklinza (daclatasvir ) taken in combination with sofosbuvir for the treatment of chronic hepatitis C genotype 3.
California-based Gilead Sciences is an American biopharmaceutical company that specializes in the development of antiviral therapies, particularly for liver diseases. Gilead actively collaborates with research institutions and healthcare organizations to boost its research capabilities and expand its portfolio in liver disease treatment.
Leading biopharma company GlaxoSmithKline PLC is headquartered in Brentford, United Kingdom, and focuses on the development of vaccine development, antiviral therapies, and innovative treatment approaches for chronic liver conditions.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi AG, AbbVie Inc., and Pfizer Inc.
Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Disease Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share